Trial Profile
A Phase II Open Label, Single-Blind, Multicenter, Single-Dose, Dose-Escalating Safety and Tolerability Study of Intrathecal Xen2174 in Oncology Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Mar 2010
Price :
$35
*
At a glance
- Drugs XEN 2174 (Primary)
- Indications Cancer pain; Various toxicities
- Focus Adverse reactions
- Sponsors Xenome